Multi-omics reveals that CTHRC1 secreted by cancer-associated fibroblasts promotes EMT by ITGA5/PI3K/AKT signaling pathway in HNSCC
Cellular Signalling · 2026
DOI: 10.1016/j.cellsig.2026.112409 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2026. Verfasst von Yang Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, 238 Jie-Fang Road, Wuhan, Hubei 430060, PR China. Hauptthemen laut MEDLINE: Cancer-Associated Fibroblasts, Extracellular Matrix Proteins, Epithelial-Mesenchymal Transition, Proto-Oncogene Proteins c-akt. Die Arbeit nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is a highly aggressive malignancy with poor prognosis. Cancer-associated fibroblasts (CAFs) in the tumor microenvironment (TME) drive tumor progression through complex cellular interactions; however, the key functional molecules and underlying mechanisms of CAFs in HNSCC remain unclear. METHODS: We employed single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) to characterize the heterogeneity of the HNSCC TME. Survival analysis, immune infiltration assessment and immune treatment response evaluation were evaluated based on TCGA and multiple GEO cohorts. Key findings were further validated through a series of functional experiments in vitro and in vivo. RESULTS: Multimodal omics analysis revealed that CTHRC1 expression was specifically enriched in the CAFs subpopulation. These CTHRC1+ CAFs were spatially co-localized with regions exhibiting epithelial-mesenchymal transition (EMT) and angiogenesis signatures in HNSCC. High infiltration of CTHRC1+ CAFs was significantly associated with poor patient prognosis. The tumor immune dysfunction and exclusion (TIDE) analysis indicated that high expression of CTHRC1 was associated with immunosuppression and adverse reactions to immunotherapy. Functional studies demonstrated that CAFs-secreted CTHRC1 directly binds to ITGA5 on tumor cells, activating the PI3K/AKT signaling pathway, thereby promoting proliferation, EMT, and angiogenesis in HNSCC. CONCLUSIONS: This study has confirmed that CTHRC1+ CAFs facilitate HNSCC malignancy via the ITGA5/PI3K/AKT signaling axis. These findings highlight CTHRC1 as a potential prognostic biomarker and therapeutic target in HNSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, 238 Jie-Fang Road, Wuhan, Hubei 430060, PR China.
- Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, 238 Jie-Fang Road, Wuhan, Hubei 430060, PR China; Department of Otolaryngology-Head and Neck Surgery, Central Laboratory, Renmin H…
- Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, 238 Jie-Fang Road, Wuhan, Hubei 430060, PR China. Electronic address: 117700199@qq.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wu, Y., Chen, T., Zuo, J., Shen, T., Dong, L., Li, F., Wang, L., & Tao, Z. (2026). Multi-omics reveals that CTHRC1 secreted by cancer-associated fibroblasts promotes EMT by ITGA5/PI3K/AKT signaling pathway in HNSCC. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2026.112409
Vancouver
Wu Y, Chen T, Zuo J, Shen T, Dong L, Li F, et al. Multi-omics reveals that CTHRC1 secreted by cancer-associated fibroblasts promotes EMT by ITGA5/PI3K/AKT signaling pathway in HNSCC. Cellular Signalling. 2026. doi:10.1016/j.cellsig.2026.112409
BibTeX
@article{Wu2026,
author = {Wu, Yang and Chen, Tian and Zuo, Jingjing and Shen, Tao and Dong, Lin and Li, Fen and Wang, Lei and Tao, Zezhang},
title = {Multi-omics reveals that CTHRC1 secreted by cancer-associated fibroblasts promotes EMT by ITGA5/PI3K/AKT signaling pathway in HNSCC},
journal = {Cellular Signalling},
year = {2026},
doi = {10.1016/j.cellsig.2026.112409}
}
EUVIMED